Hofseth Biocare ASA: Financial Update
October 10 2017 - 4:18AM
Based on preliminary figures
for the Third Quarter 2017, Hofseth BioCare ASA (HBC) management
expects to report group revenues of approximately NOK 28m for the
quarter, compared to NOK 3.6m in the same quarter 2016.
The cash balance by the end
of Q3 was approx. NOK 30m. HBC will report 3rd quarter 2017
financial results 15th November 2017.
For further information,
please contact:
Roger Hofseth, CEO of
Hofseth BioCare ASA
Mob: +47 95147941
E-mail: rh@hofseth-as.no
Jon Olav Ødegård, CFO of
Hofseth BioCare ASA
Mob: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value
ingredients and finished products for humans and pets. The company
is founded on the core values of sustainability, traceability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC is able to preserve the quality of
salmon oil, proteins and calcium, prepared of fresh salmon
off-cuts. HBC's objective is to contribute to the efficient use of
marine resources and deliver quality products for ingredients and
finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with
branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo
Stock Exchange Axess list with ticker "HBC". More information about
Hofseth BioCare at www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire